



[www.MedChemExpress.com](http://www.MedChemExpress.com)

Inhibitors, Agonists, Screening Libraries

# Monoamine Oxidase

## MAO


Monoamine oxidases (MAO) are a family of enzymes that catalyze the oxidation of monoamines. They are found bound to the outer membrane of mitochondria in most cell types in the body. They belong to the protein family of flavin-containing amine oxidoreductases. Monoamine oxidases catalyze the oxidative deamination of monoamines. Oxygen is used to remove an amine group from a molecule, resulting in the corresponding aldehyde and ammonia. Monoamine oxidases contain the covalently bound cofactor FAD and are, thus, classified as flavoproteins. Because of the vital role that MAOs play in the inactivation of neurotransmitters, MAO dysfunction is thought to be responsible for a number of psychiatric and neurological disorders. MAO-A inhibitors act as antidepressant and anti-anxiety agents, whereas MAO-B inhibitors are used alone or in combination to treat Alzheimer's and Parkinson's diseases.

## Monoamine Oxidase Inhibitors

### (2-Chloropyridin-4-yl)methanamine hydrochloride

Cat. No.: HY-101771A

(2-Chloropyridin-4-yl)methanamine hydrochloride is a selective LOXL2 inhibitor with an  $IC_{50}$  of 126 nM.




**Purity:** 98.70%  
**Clinical Data:** No Development Reported  
**Size:** 10 mM × 1 mL, 100 mg

### (rel)-Tranlycypromine D5 hydrochloride

(2-Phenylcyclopropylamine D5 hydrochloride)

Cat. No.: HY-174475A

(rel)-Tranlycypromine D5 hydrochloride (2-Phenylcyclopropylamine D5 hydrochloride) is a deuterium labeled (rel)-Tranlycypromine hydrochloride.



Relative stereochemistry


**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 5 mg

### (S)-Rasagiline

(TVP1022; S-PAI)

Cat. No.: HY-14200

(S)-Rasagiline (TVP1022) is the relatively inactive S-enantiomer form of Rasagiline. Rasagiline is a highly potent selective irreversible MAO inhibitor with  $IC_{50}$ s of 4.43nM and 412nM for rat brain MAO B and A activity, respectively.




**Purity:** 99.60%  
**Clinical Data:** Launched  
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

### (S)-Rasagiline mesylate

(TVP1022 mesylate; S-PAI mesylate)

Cat. No.: HY-14200A

(S)-Rasagiline (TVP1022) mesylate is the relatively inactive S-enantiomer form of Rasagiline mesylate. Rasagiline mesylate is a highly potent selective irreversible MAO inhibitor with  $IC_{50}$ s of 4.43nM and 412nM for rat brain MAO B and A activity, respectively.




**Purity:** >98%  
**Clinical Data:** Launched  
**Size:** 1 mg, 5 mg

### (±)-Amiflamine

(FLA 336)

Cat. No.: HY-119885A

(±)-Amiflamine (FLA 336) is a potent monoamine oxidase-A (MAO-A) inhibitor with a  $pIC_{50}$  of 5.57.




**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg

### 2614W94

Cat. No.: HY-101578

2614W94 is a selective, reversible inhibitor of monoamine oxidase-A with a competitive mechanism of inhibition and  $IC_{50}$  of 5 nM and  $K_i$  of 1.6 nM with serotonin as substrate.




**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg

### 4-Hydroxyderricin

Cat. No.: HY-N7204

4-Hydroxyderricin, the major active ingredients of Angelica keiskei Koidzumi, is a potent selective MAO-B (Monoamine oxidase inhibitors) inhibitor with an  $IC_{50}$  of 3.43  $\mu$ M. 4-Hydroxyderricin also mildly inhibits DBH (dopamine  $\beta$ -hydroxylase) activity.




**Purity:** 95.01%  
**Clinical Data:** No Development Reported  
**Size:** 5 mg

### 7-Hydroxy-3,4-dihydro-2(1H)-quinolinone

(3,4-Dihydro-7-hydroxy-2(1H)-quinolinone)

Cat. No.: HY-W010130

7-Hydroxy-3,4-dihydro-2(1H)-quinolinone (3,4-Dihydro-7-hydroxy-2(1H)-quinolinone) is a weak MAO-A inhibitor, with an  $IC_{50}$  of 183  $\mu$ M, and has no effect on MAO-B.




**Purity:** 99.96%  
**Clinical Data:** No Development Reported  
**Size:** 10 mM × 1 mL, 100 mg

### Amitraz

(BTS-27419)

Cat. No.: HY-B1111

Amitraz is a non-systemic acaricide and insecticide, with alpha-adrenergic agonist activity, interaction with octopamine receptors of the central nervous system and inhibition of monoamine oxidases and prostaglandin synthesis.




**Purity:**  $\geq$ 98.0%  
**Clinical Data:** No Development Reported  
**Size:** 10 mM × 1 mL, 100 mg

### Azure B











(Azure B chloride)











Cat. No.: HY-D0004

Azure B is a cationic dye and the major metabolite of Methylene blue. Azure B is used in making Azure eosin stains for blood smear staining.























**Purity:** 96.08%  
**Clinical Data:** No Development Reported  
**Size:** 5 mg

<p><b>Bifemelane hydrochloride</b> (MCI-2016)</p> <p style="text-align: right;">Cat. No.: HY-B1558A</p>	<p><b>Brofaromine</b> (CGP 11305A)</p> <p style="text-align: right;">Cat. No.: HY-13339</p>
<p>Bifemelane hydrochloride (MCI-2016) is a potent, selective and competitive inhibitor of <b>monoamine oxidase A (MAO-A)</b>, with a <math>K_i</math> of 4.20 <math>\mu</math>M. Bifemelane hydrochloride also inhibits <b>MAO-B</b> noncompetitively with a <math>K_i</math> of 46.0 <math>\mu</math>M.</p>  <p><b>Purity:</b> 98.83% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p>Brofaromine (CGP 11305A) is a <b>monoamine oxidase (MAO)</b> inhibitor with <math>IC_{50}</math> of 0.2<math>\mu</math>M for <b>MAO-A</b>.</p>  <p><b>Purity:</b> 98.55% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p>
<p><b>CCT365623 hydrochloride</b></p> <p style="text-align: right;">Cat. No.: HY-124674A</p>	<p><b>Chrysophanol-1-O-<math>\beta</math>-gentiobioside</b></p> <p style="text-align: right;">Cat. No.: HY-N7598</p>
<p>CCT365623 hydrochloride is an orally active <b>lysyl oxidase (LOX)</b> inhibitor, with an <math>IC_{50}</math> of 0.89 <math>\mu</math>M. CCT365623 hydrochloride suppresses EGFR (pY1068) and AKT phosphorylation driven by EGF. CCT365623 hydrochloride is extremely well tolerated, and has good pharmacokinetic properties.</p>  <p><b>Purity:</b> <math>\geq</math>98.0% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p>Chrysophanol-1-O-<math>\beta</math>-gentiobioside, an anthraquinone glycoside isolated from <i>Cassia obtusifolia</i> seeds. Chrysophanol-1-O-<math>\beta</math>-gentiobioside shows selective inhibition of hMAO-A isozyme activity (<math>IC_{50}</math>=96.15 <math>\mu</math>M).</p>  <p><b>Purity:</b> <math>&gt;</math>98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg</p>
<p><b>Clorgyline hydrochloride</b></p> <p style="text-align: right;">Cat. No.: HY-14197A</p>	<p><b>Contezolid</b> (MRX-I)</p> <p style="text-align: right;">Cat. No.: HY-19915</p>
<p>Clorgyline hydrochloride is an irreversible and selective inhibitor of monoamine oxidase A (MAO-A) that is used in scientific research; structurally related to Pargyline.</p>  <p><b>Purity:</b> 99.70% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mM <math>\times</math> 1 mL, 10 mg, 50 mg, 100 mg, 500 mg</p>	<p>Contezolid (MRX-I), a new and orally active oxazolidinone, is an antibiotic in study for complicated skin and soft tissue infections (cSSTI) caused by resistant Gram-positive bacteria.</p>  <p><b>Purity:</b> <math>&gt;</math>98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b>CX-157</b></p> <p style="text-align: right;">Cat. No.: HY-100178</p>	<p><b>Desmethoxyyangonin</b> (Demethoxyyangonin; 5,6-Dehydrokavain)</p> <p style="text-align: right;">Cat. No.: HY-N0918</p>
<p>CX-157 is a reversible inhibitor of <b>monoamine oxidase-A (MAO-A)</b> with an <math>EC_{50}</math> of 19.3ng/mL.</p>  <p><b>Purity:</b> <math>&gt;</math>98% <b>Clinical Data:</b> Phase 2 <b>Size:</b> 1 mg, 5 mg</p>	<p>Desmethoxyyangonin is one of the six major kavalactones found in the <i>Piper methysticum</i> (kava) plant; reversible inhibitor of MAO-B.</p>  <p><b>Purity:</b> <math>\geq</math>98.0% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 5 mg, 10 mg</p>
<p><b>Eprobemide</b> (LIS 630)</p> <p style="text-align: right;">Cat. No.: HY-B1413</p>	<p><b>Glicoricone</b></p> <p style="text-align: right;">Cat. No.: HY-N9329</p>
<p>Eprobemide is a non-competitive reversible inhibitor of <b>monoamine oxidase A</b>.</p>  <p><b>Purity:</b> 99.63% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p>Glicoricone, a phenolic compound, is isolated from a species of licorice. Glicoricone is an inhibitor of <b>monoamine oxidase (MAO)</b>, with an <math>IC_{50}</math> of 140 <math>\mu</math>M. Glicoricone binds to <b>estrogen receptor (ER)</b> and shows estrogen antagonist activity.</p>  <p><b>Purity:</b> <math>&gt;</math>98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>

<p><b>GSK-LSD1 dihydrochloride</b></p> <p>Cat. No.: HY-100546A</p> <p>GSK-LSD1 dihydrochloride is a potent, selective and irreversible lysine specific demethylase 1 (LSD1) inhibitor with an <math>IC_{50}</math> of 16 nM.</p>  <p>H-Cl H-Cl</p> <p><b>Purity:</b> ≥98.0%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg</p>	<p><b>Harmane</b></p> <p>Cat. No.: HY-101392</p> <p>Harmane, a β-Carboline alkaloid (BCA), is a potent neurotoxin that causes severe action tremors and psychiatric manifestations. Harmane shows 1000-fold selectivity for <b>11-Imidazoline receptor</b> (<math>IC_{50}</math>=30 nM) over <b>α2-adrenoceptor</b> (<math>IC_{50}</math>=18 μM).</p>  <p><b>Purity:</b> 99.73%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 100 mg</p>
<p><b>Hydroxyamine hydrochloride</b></p> <p>Cat. No.: HY-Y0882</p> <p>Hydroxyamine hydrochloride is a selective <b>monoamine oxidase (MAO)</b> inhibitor used for inhibiting of platelet aggregation. Hydroxyamine hydrochloride is an intermediate of organic synthesis.</p>  <p>H<sub>2</sub>N-OH H-Cl</p> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 500 mg</p>	<p><b>Iproniazid</b></p> <p>Cat. No.: HY-B0886A</p> <p>Iproniazid is a non-selective, irreversible <b>monoamine oxidase (MAO)</b> inhibitor of the hydrazine class. Iproniazid has antidepressive activity.</p>  <p><b>Purity:</b> ≥98.0%  <b>Clinical Data:</b> Launched  <b>Size:</b> 10 mM × 1 mL, 100 mg</p>
<p><b>Iproniazid phosphate</b></p> <p>Cat. No.: HY-B0886</p> <p>Iproniazid phosphate is a non-selective, irreversible <b>monoamine oxidase (MAO)</b> inhibitor of the hydrazine class. Iproniazid phosphate has antidepressive activity.</p>  <p><b>Purity:</b> 99.92%  <b>Clinical Data:</b> Launched  <b>Size:</b> 10 mM × 1 mL, 100 mg</p>	<p><b>Isatin</b> (Indoline-2,3-dione)</p> <p>Cat. No.: HY-Y0265</p> <p>Isatin (Indoline-2,3-dione) is a potent inhibitor of <b>monoamine oxidase (MAO)</b> with an <math>IC_{50}</math> of 3 μM. Also binds to central benzodiazepine receptors (<math>IC_{50}</math> against clonazepam, 123 μM).</p>  <p><b>Purity:</b> 97.36%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 10 mM × 1 mL, 100 mg</p>
<p><b>Isocarboxazid</b></p> <p>Cat. No.: HY-13929</p> <p>Isocarboxazid is a non-selective and irreversible inhibitor of <b>monoamine oxidase</b>, with an <math>IC_{50}</math> of 4.8 μM for rat brain monoamine oxidase in vitro.</p>  <p><b>Purity:</b> ≥98.0%  <b>Clinical Data:</b> Launched  <b>Size:</b> 10 mM × 1 mL, 5 mg</p>	<p><b>J-147</b></p> <p>Cat. No.: HY-13779</p> <p>J-147 is an exceptionally potent, orally active, neuroprotective agent for cognitive enhancement. J-147 can readily pass the blood brain barrier (BBB).</p>  <p><b>Purity:</b> 99.87%  <b>Clinical Data:</b> Phase 1  <b>Size:</b> 10 mM × 1 mL, 5 mg, 10 mg, 50 mg</p>
<p><b>Ladostigil</b> (TV-3326)</p> <p>Cat. No.: HY-10399</p> <p>Ladostigil (TV-3326) is a dual inhibitor of <b>cholinesterase</b> and brain-selective <b>monoamine oxidase (MAO)</b>, with an <math>IC_{50}</math> of 37.1 and 31.8 μM for MAO-B and AChE, respectively.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Lazabemide</b> (Ro 19-6327)</p> <p>Cat. No.: HY-14201</p> <p>Lazabemide (Ro 19-6327) is a selective, reversible inhibitor of monoamine oxidase B (MAO-B) (<math>IC_{50}</math>=0.03 μM) but less active for MAO-A (<math>IC_{50}</math>&gt;100 μM).</p>  <p><b>Purity:</b> 99.76%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 10 mM × 1 mL, 10 mg, 50 mg</p>

<p><b>Lazabemide hydrochloride</b> (Ro 19-6327 hydrochloride)</p> <p>Lazabemide hydrochloride (Ro 19-6327 hydrochloride) is a selective, reversible inhibitor of <b>monoamine oxidase B (MAO-B)</b> (<math>IC_{50}=0.03 \mu\text{M}</math>) but less active for MAO-A (<math>IC_{50}&gt;100 \mu\text{M}</math>).</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b>LOX-IN-3</b></p> <p>LOX-IN-3 is an orally active <b>lysyl oxidase (LOX)</b> inhibitor. LOX-IN-3 can be used for fibrosis, cancer and/or angiogenesis research.</p> <p><b>Purity:</b> 99.51% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>
<p><b>LOX-IN-3 dihydrochloride</b></p> <p>LOX-IN-3 dihydrochloride is an orally active <b>lysyl oxidase (LOX)</b> inhibitor. LOX-IN-3 dihydrochloride can be used for fibrosis, cancer and/or angiogenesis research.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b>MAO-B-IN-1</b></p> <p>MAO-B-IN-1 is an inhibitor of <b>monoamine oxidase B</b>, used for the research of neurological diseases.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b>MAO-IN-1</b></p> <p>MAO-IN-1 is a monoamine oxidase B (<b>MAO B</b>) inhibitor with an <math>IC_{50}</math> of 20 nM.</p> <p><b>Purity:</b> ≥99.0% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg, 10 mg, 20 mg</p>	<p><b>MAO-IN-M30 dihydrochloride</b></p> <p>MAO-IN-M30 dihydrochloride is an orally active, brain-permeable, and brain selective irreversible <b>MAO-A</b> (<math>IC_{50}=37 \text{ nM}</math>) and <b>MAO-B</b> (<math>IC_{50}=57 \text{ nM}</math>) inhibitor. MAO-IN-M30 dihydrochloride is a potent <b>iron chelator</b> and <b>radical scavenger</b>.</p> <p><b>Purity:</b> ≥98.0% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 5 mg</p>
<p><b>Methylene Blue</b> (Basic Blue 9; Cl-52015; Methylthionium chloride)</p> <p>Methylene blue (Basic Blue 9) is a <b>guanylyl cyclase (sGC)</b>, <b>monoamine oxidase A (MAO-A)</b> and <b>NO synthase (NOS)</b> inhibitor. Methylene blue is a vasopressor and is often used as a dye in several medical procedures.</p> <p><b>Purity:</b> ≥98.0% <b>Clinical Data:</b> Launched <b>Size:</b> 100 mg, 500 mg</p>	<p><b>Methylene blue trihydrate</b> (C.I. Basic Blue 9 trihydrate)</p> <p>Methylene blue trihydrate (C.I. Basic Blue 9 trihydrate) is a <b>guanylyl cyclase (sGC)</b>, <b>monoamine oxidase A (MAO-A)</b> and <b>NO synthase (NOS)</b> inhibitor. Methylene blue trihydrate is a vasopressor and is often used as a dye in several medical procedures.</p> <p><b>Purity:</b> ≥97.0% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM × 1 mL, 100 mg, 500 mg</p>
<p><b>Minaprine</b></p> <p>Minaprine is a reversible inhibitor of MAO-A; weakly inhibit acetylcholinesterase; an antidepressant for treatment of depression.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> Launched <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Minaprine dihydrochloride</b></p> <p>Minaprine dihydrochloride is a reversible inhibitor of MAO-A; weakly inhibit acetylcholinesterase; an antidepressant for treatment of depression.</p> <p><b>Purity:</b> 99.61% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mM × 1 mL, 100 mg</p>

<p><b>Moclobemide</b> (Ro111163) <span style="float: right;">Cat. No.: HY-B0534</span></p> <p>Moclobemide(Ro111163) is a reversible monoamine oxidase inhibitor (MAOI) selective for isoform A (RIMA) used to treat major depressive disorder.</p>  <p><b>Purity:</b> 99.63% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM × 1 mL, 50 mg, 100 mg</p>	<p><b>Modaline sulfate</b> <span style="float: right;">Cat. No.: HY-B1083</span></p> <p>Modaline sulfate is a MAOI used in the treatment of depression.</p>  <p><b>Purity:</b> 98.95% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mM × 1 mL, 100 mg</p>
<p><b>Mofegiline hydrochloride</b> (MDL72974A) <span style="float: right;">Cat. No.: HY-16677A</span></p> <p>Mofegiline hydrochloride (MDL72974A) is a potent and selective enzyme-activated irreversible inhibitor of MAO-B; shows marked selectivity for the B form (IC<sub>50</sub> = 680 and 3.6 nM for MAO-A and MAO-B).</p>  <p><b>Purity:</b> ≥95.0% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p>	<p><b>Nialamide</b> <span style="float: right;">Cat. No.: HY-B1199</span></p> <p>Nialamide is a non-selective, irreversible monoamine oxidase inhibitor (MAOI) of the hydrazine class that was used as an antidepressant.</p>  <p><b>Purity:</b> ≥95.0% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 100 mg</p>
<p><b>Norharmane</b> (Norharman; β-Carboline) <span style="float: right;">Cat. No.: HY-W008566</span></p> <p>Norharmane (Norharman) is a potent and selective monoamine oxidase A (MAO-A) inhibitor with a K<sub>i</sub> of 3.34 μM.</p>  <p><b>Purity:</b> ≥95.0% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mM × 1 mL, 100 mg</p>	<p><b>Obtusin</b> <span style="float: right;">Cat. No.: HY-N6057</span></p> <p>Obtusin, isolated from Cassia obtusifolia Linn seed, is a highly selective and competitive human monoamine oxidase-A (hMAO-A) inhibitor with an IC<sub>50</sub> of 11.12 μM and a K<sub>i</sub> of 6.15 μM. Obtusin plays a preventive role in neurodegenerative diseases, especially anxiety and depression.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b>OG-L002</b> <span style="float: right;">Cat. No.: HY-19333</span></p> <p>OG-L002 is a potent and highly selective LSD1 inhibitor with an IC<sub>50</sub> of 0.02 μM. OG-L002 is a potent monoamine oxidases (MAO) inhibitor with IC<sub>50</sub>s of 1.38 μM and 0.72 μM for MAO-A and MAO-B, respectively. OG-L002 potently inhibits the expression of HSV IE genes.</p>  <p><b>Purity:</b> 99.71% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mM × 1 mL, 5 mg, 10 mg, 50 mg</p>	<p><b>Osthenol</b> (Ostenol) <span style="float: right;">Cat. No.: HY-N2554</span></p> <p>Osthenol (Ostenol), a prenylated coumarin isolated from the dried roots of Angelica pubescens, is selective, reversible, and competitive human monoamine oxidase-A (hMAO-A) inhibitor (K<sub>i</sub>=0.26 μM).</p>  <p><b>Purity:</b> 98.91% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg</p>
<p><b>Paeonol</b> <span style="float: right;">Cat. No.: HY-N0159</span></p> <p>Paeonol is an active extraction from the root of Paeonia suffruticosa, Paeonol inhibits MAO-A and MAO-B with IC<sub>50</sub> of 54.6 μM and 42.5 μM, respectively.</p>  <p><b>Purity:</b> 99.86% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM × 1 mL, 500 mg, 1 g</p>	<p><b>Pargyline</b> <span style="float: right;">Cat. No.: HY-A0091A</span></p> <p>Pargyline is an irreversible monoamine oxidase (MAO) inhibitor with K<sub>s</sub> of 13 μM and 0.5 μM for MAO-A and MAO-B, respectively. Pargyline has antihypertensive and anticancer activities.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> Launched <b>Size:</b> 1 mg, 5 mg</p>

<p><b>Pargyline hydrochloride</b></p> <p>Cat. No.: HY-A0091</p> <p>Pargyline hydrochloride is an irreversible <b>monoamine oxidase (MAO)</b> inhibitor with <math>K_i</math>s of 13 <math>\mu</math>M and 0.5 <math>\mu</math>M for MAO-A and MAO-B, respectively. Pargyline hydrochloride has antihypertensive and anticancer activities.</p> <p><b>Purity:</b> 99.91%  <b>Clinical Data:</b> Launched  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 500 mg</p> 	<p><b>PAT-1251</b></p> <p>Cat. No.: HY-107422</p> <p>PAT-1251 is a potent, selective and oral lysyl oxidase-like 2 (LOXL2) inhibitor, with <math>IC_{50}</math>s of 0.71 and 1.17 <math>\mu</math>M for hLOXL2 and hLOXL3, respectively, and also potently inhibits mouse, rat, and dog LOXL2 (<math>IC_{50}</math>s, 0.10, 0.12, and 0.16 <math>\mu</math>M, respectively); PAT-1251 is used in...</p> <p><b>Purity:</b> 98.17%  <b>Clinical Data:</b> Phase 2  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 
<p><b>PAT-1251 Hydrochloride</b></p> <p>Cat. No.: HY-107422A</p> <p>PAT-1251 Hydrochloride is a potent, selective and oral lysyl oxidase-like 2 (LOXL2) inhibitor, with <math>IC_{50}</math>s of 0.71 and 1.17 <math>\mu</math>M for hLOXL2 and hLOXL3, respectively, and also potently inhibits mouse, rat, and dog LOXL2 (<math>IC_{50}</math>s, 0.10, 0.12, and 0.16 <math>\mu</math>M, respectively).</p> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> Phase 2  <b>Size:</b> 1 mg, 5 mg</p> 	<p><b>PXS-4728A</b></p> <p>Cat. No.: HY-112726</p> <p>PXS-4728A is a selective, orally active inhibitor of semicarbazide-sensitive amine oxidase (SSAO). PXS-4728A ameliorates chronic obstructive pulmonary disease in mice.</p> <p><b>Purity:</b> 98.18%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 
<p><b>PXS-5120A</b></p> <p>Cat. No.: HY-130242</p> <p>PXS-5120A is a potent, irreversible fluoroallylamine inhibitor of <b>Lysyl Oxidase-like 2/3 (LOXL2/3)</b> with anti-fibrotic activity. PXS-5120A is &gt;300-fold selective for LOXL2 (<math>K_i</math> of 83 nM; <math>pIC_{50}</math> of 8.4) over LOXL3 (<math>pIC_{50}</math> of 5.8).</p> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p> 	<p><b>PXS-5153A</b></p> <p>Cat. No.: HY-114286</p> <p>PXS-5153A is a potent, selective, orally active and fast-acting lysyl oxidase like 2/3 enzymatic (LOXL2/LOXL3) inhibitor, with an <math>IC_{50}</math> of &lt;40 nM for LOXL2 across all mammalian species and an <math>IC_{50}</math> of 63 nM for human LOXL3. PXS-5153A could reduce crosslinks and ameliorates fibrosis.</p> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p> 
<p><b>PXS-5153A monohydrochloride</b></p> <p>Cat. No.: HY-114286A</p> <p>PXS-5153A monohydrochloride is a potent, selective, orally active and fast-acting lysyl oxidase like 2/3 enzymatic (LOXL2/LOXL3) inhibitor, with an <math>IC_{50}</math> of &lt;40 nM for LOXL2 across all mammalian species and an <math>IC_{50}</math> of 63 nM for human LOXL3.</p> <p><b>Purity:</b> 99.67%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 	<p><b>Rasagiline</b></p> <p>(R)-AGN1135; TVP1012</p> <p>Cat. No.: HY-14605A</p> <p>Rasagiline (R-AGN1135) is a highly potent selective irreversible <b>mitochondrial monoamine oxidase (MAO)</b> inhibitor with <math>IC_{50}</math>s of 4.43nM and 412nM for rat brain MAO B and A activity, respectively.</p> <p><b>Purity:</b> 98.84%  <b>Clinical Data:</b> Launched  <b>Size:</b> 50 mg, 100 mg, 250 mg</p> 
<p><b>Rasagiline 13C3 mesylate racemic</b></p> <p>(AGN1135 13C3; TVP1012 13C3 racemic)</p> <p>Cat. No.: HY-14605BS</p> <p>Rasagiline 13C3 mesylate racemic is the deuterium labeled Rasagiline mesylate racemic. Rasagiline mesylate racemic is a highly potent selective irreversible <b>mitochondrial monoamine oxidase (MAO)</b> inhibitor.</p> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> Phase 4  <b>Size:</b> 1 mg, 5 mg</p> 	<p><b>Rasagiline mesylate</b></p> <p>(R)-AGN1135 mesylate; TVP1012 mesylate)</p> <p>Cat. No.: HY-14605</p> <p>Rasagiline (R-AGN1135) mesylate is a highly potent selective irreversible <b>mitochondrial monoamine oxidase (MAO)</b> inhibitor with <math>IC_{50}</math>s of 4.43nM and 412nM for rat brain MAO B and A activity, respectively.</p> <p><b>Purity:</b> 99.66%  <b>Clinical Data:</b> Launched  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 50 mg, 100 mg</p> 

<p><b>Ro 41-1049 hydrochloride</b></p> <p style="text-align: right;">Cat. No.: HY-100027A</p>	<p><b>Rosiridin</b></p> <p style="text-align: right;">Cat. No.: HY-N0505</p>
<p>Ro 41-1049 hydrochloride is a reversible and selective inhibitor of <b>monoamine oxidase-A (MAO-A)</b>.</p> <p><b>Purity:</b> 99.96%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p>	<p>Rosiridin, which is isolated from <i>Rhodiola rosea</i> L., inhibits <b>MAO A</b> and <b>MAO B</b> with potential beneficial effect in depression and senile dementia. Rosiridin shows an inhibition of 83.8% against MAO B at 10 μM (pIC<sub>50</sub>=5.38).</p> <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg, 5 mg, 10 mg</p>
<p><b>Rosmarinic acid</b> (Labiatic acid)</p> <p style="text-align: right;">Cat. No.: HY-N0529</p>	<p><b>RS 8359</b></p> <p style="text-align: right;">Cat. No.: HY-14260</p>
<p>Rosmarinic acid is a widespread phenolic ester compound in the plants. Rosmarinic acid inhibits <b>MAO-A</b>, <b>MAO-B</b> and <b>COMT</b> enzymes with IC<sub>50</sub>s of 50.1, 184.6 and 26.7 μM, respectively.</p> <p><b>Purity:</b> 99.29%</p> <p><b>Clinical Data:</b> Phase 4</p> <p><b>Size:</b> 10 mM × 1 mL, 50 mg, 100 mg</p>	<p>RS 8359 is a selective and reversible <b>MAO-A</b> inhibitor, with antidepressant activity.</p> <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg, 5 mg</p>
<p><b>Rubrofusarin triglucoside</b></p> <p style="text-align: right;">Cat. No.: HY-N7603</p>	<p><b>Safinamide</b> (FCE 26743; EMD 1195686)</p> <p style="text-align: right;">Cat. No.: HY-70057</p>
<p>Rubrofusarin triglucoside is a glycoside compound isolated from <i>Cassia obtusifolia</i> Linn seeds. Rubrofusarin triglucoside inhibits <b>human monoamine oxidase A (hMAO-A)</b> with an IC<sub>50</sub> of 85.5 μM.</p> <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg</p>	<p>Safinamide is a potent, selective, and reversible <b>monoamine oxidase B (MAO-B)</b> inhibitor (IC<sub>50</sub>=0.098 μM) over MAO-A (IC<sub>50</sub>=580 μM).</p> <p><b>Purity:</b> 99.95%</p> <p><b>Clinical Data:</b> Launched</p> <p><b>Size:</b> 10 mM × 1 mL, 10 mg, 50 mg</p>
<p><b>Safinamide mesylate</b> (FCE 26743 mesylate; EMD 1195686 mesylate)</p> <p style="text-align: right;">Cat. No.: HY-70057A</p>	<p><b>Salsolidine</b> (6,7-Dimethoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline)</p> <p style="text-align: right;">Cat. No.: HY-22385</p>
<p>Safinamide (FCE 26743; EMD 1195686) mesylate is a potent, selective, and reversible <b>monoamine oxidase B (MAO-B)</b> inhibitor (IC<sub>50</sub>=0.098 μM) over MAO-A (IC<sub>50</sub>=580 nM).</p> <p><b>Purity:</b> 99.18%</p> <p><b>Clinical Data:</b> Launched</p> <p><b>Size:</b> 10 mM × 1 mL, 10 mg, 50 mg</p>	<p>Salsolidine is a tetrahydroisoquinoline alkaloid, acts as a stereoselective competitive <b>MAO A</b> inhibitor.</p> <p><b>Purity:</b> ≥95.0%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 10 mM × 1 mL, 25 mg, 50 mg, 100 mg</p>
<p><b>TB5</b></p> <p style="text-align: right;">Cat. No.: HY-100975</p>	<p><b>Toloxatone</b> (MD 69276)</p> <p style="text-align: right;">Cat. No.: HY-14196</p>
<p>TB5 is a potent, selective and reversible inhibitor of <b>hMAO-B</b> with a K<sub>i</sub> value of 0.11±0.01 μM.</p> <p><b>Purity:</b> ≥95.0%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 10 mM × 1 mL, 50 mg, 100 mg</p>	<p>Toloxatone (MD 69276) is a reversible <b>monoamine oxidase A (MAO<sub>A</sub>)</b> inhibitor. Antidepressant.</p> <p><b>Purity:</b> 99.34%</p> <p><b>Clinical Data:</b> Launched</p> <p><b>Size:</b> 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>



